At SkylineDx, we live to make a difference. It is our mission to improve a patient’s quality of life by enabling them to benefit from personal insights at the genomic level of their disease. That means we are continuously innovating the world of gene signature-based diagnostic testing.
Approximately 100,000 Americans are diagnosed annually with melanoma. Each patient requires staging to determine an optimal treatment strategy. It is crucial to assess whether the cancer has spread to the sentinel lymph nodes which might indicate additional risk for patients. The Merlin Test helps answering the question “Can this patient safely forgo a Sentinel Lymph Node Biopsy?”. At the core of this Test is a proprietary algorithm, called the CP-GEP model. CP-GEP interrogates 8 genes of interest, directly correlated to risk of nodal metastasis, and integrates clinicopathologic variables (patient age and Breslow thickness) into the analysis. The model is able to predict a melanoma patient’s nodal metastatic risk without an invasive Sentinel Lymph Node Biopsy surgery. Ongoing extensive validation studies in the US and EU have confirmed that the test accurately stratifies low- and high-risk patients.
Facebook
Twitter
LinkedIn
Forward